Ionis completes subject enrolment in Alexander disease treatment trial
Topline data from the trial are expected in the second half of 2025.
Neurology
Ivy Brain Tumor Center announces dosing of first subject in glioblastoma trial
Anxiety identified as major indicator of Parkinson’s disease in older adults
EAN 2024: Opicapone demonstrates efficacy in real-world clinical practice
IntelGenx reports preliminary data from Phase IIa Alzheimer’s disease trial
EAN 2024: Benefits of early migraine treatment clear but implementation remains challenging
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial
AskBio commences subject recruitment in Phase II Parkinson’s trial
